Rectal morbidity after permanent prostate brachytherapy with dose escalation to biologic target volumes identified by SPECT/CT fusion

Brachytherapy

Volumn 6, Issue 2, 2007, Pages 149-156

  Ellis, Rodney J ^a,b,c   Zhou, Hang ^c,d   Kaminsky, Deborah A ^a   Fu, Pingfu ^c   Kim, Edward Y ^c,d   Sodee, D Bruce ^c,d   Colussi, Valdir ^c,d   Spirnak, John P ^c,e   Whalen, Christopher C ^c   Resnick, Martin I ^c,d  

^a AULTMAN HOSPITAL   (United States)

^b Northeast Ohio Medical University   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^e METROHEALTH MEDICAL CENTER   (United States)

Author keywords

ProstaScint; Prostate brachytherapy; Quality of life; Rectal morbidity; SPECT CT

Indexed keywords

CAPROMAB PENDETIDE IN 111; IODINE 125; PALLADIUM 103;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NECROSIS; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RECTUM DISEASE; RECTUM FISTULA; RECTUM HEMORRHAGE; RECTUM PERFORATION; SCORING SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BRACHYTHERAPY; FOLLOW-UP STUDIES; GASTROINTESTINAL MOTILITY; HUMANS; IODINE RADIOISOTOPES; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM STAGING; PALLADIUM; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOMETRY; RADIOTHERAPY DOSAGE; RECTUM; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 34047268425     PISSN: 15384721     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brachy.2007.01.006     Document Type: Article

References (43)

1. Quaranta B.P., Marks L.B., and Anscher M.S. Comparing radical prostatectomy and brachytherapy for localized prostate cancer. Oncology (Huntingt) 18 (2004) 1289-1302 discussion 302-304, 309
2. Potters L., Klein E.A., Kattan M.W., et al. Monotherapy for stage T1-T2 prostate cancer: Radical prostatectomy, external beam radiotherapy, or permanent seed implantation. Radiother Oncol 71 (2004) 29-33
3. Merrick G.S., and Butler W.M. Rectal function following permanent prostate brachytherapy. WV Med J 100 (2004) 18-20
4. Gelblum D.Y., and Potters L. Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys 48 (2000) 119-124
5. Merrick G.S., Butler W.M., Dorsey A.T., et al. Rectal dosimetric analysis following prostate brachytherapy. Int J Radiat Oncol Biol Phys 43 (1999) 1021-1027
6. Wallner K., Roy J., and Harrison L. Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys 32 (1995) 465-471
7. Waterman F.M., and Dicker A.P. Probability of late rectal morbidity in 125I prostate brachytherapy. Int J Radiat Oncol Biol Phys 55 (2003) 342-353
8. Snyder K.M., Stock R.G., Hong S.M., et al. Defining the risk of developing grade 2 proctitis following 125I prostate brachytherapy using a rectal dose-volume histogram analysis. Int J Radiat Oncol Biol Phys 50 (2001) 335-341
9. Merrick G.S., Butler W.M., Wallner K.E., et al. Rectal function following brachytherapy with or without supplemental external beam radiation: Results of two prospective randomized trials. Brachytherapy 2 (2003) 147-157
10. Nag S., Ellis R.J., Merrick G.S., et al. American Brachytherapy Society recommendations for reporting morbidity after prostate brachytherapy. Int J Radiat Oncol Biol Phys 54 (2002) 462-470
11. Shah J.N., and Ennis R.D. Rectal toxicity profile after transperineal interstitial permanent prostate brachytherapy: Use of a comprehensive toxicity scoring system and identification of rectal dosimetric predictors. Int J Radiat Oncol Biol Phys 64 (2006) 817-824
12. Caffo O., Fellin G., Bolner A., et al. Prospective evaluation of quality of life after interstitial brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 66 (2006) 31-37
13. Davis J.W., and Schellhammer P.F. Prostatorectal fistula 14 years following brachytherapy for prostate cancer. J Urol 165 (2001) 8-9
14. Feigenberg S.J., Lee W.R., Desilvio M.L., et al. Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05. Int J Radiat Oncol Biol Phys 62 (2005) 956-964
15. Miller D.C., Sanda M.G., Dunn R.L., et al. Long-term outcomes among localized prostate cancer survivors: Health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. J Clin Oncol 23 (2005) 2772-2780
16. Shah J.N., and Ennis R.D. Rectal toxicity profile after transperineal interstitial permanent prostate brachytherapy: Use of a comprehensive toxicity scoring system and identification of rectal dosimetric toxicity predictors. Int J Radiat Oncol Biol Phys 64 (2006) 817-824
17. Zagar T.M., Stock R.G., Cesaretti J.A., et al. Assessment of postbrachytherapy sexual function: A comparison of the IIEF-5 and the MSEFS. Brachytherapy 6 (2007) 26-33
18. Grado G.L. Techniques to achieve optimal seed placement in salvage and primary brachytherapy for prostate cancer. Tech Urol 6 (2000) 157-165
19. Sylvester J.E., Blasko J.C., Grimm P.D., et al. Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: The Seattle experience. Int J Radiat Oncol Biol Phys 57 (2003) 944-952
20. D'Souza W.D., Thames H.D., and Kuban D.A. Dose-volume conundrum for response of prostate cancer to brachytherapy: Summary dosimetric measures and their relationship to tumor control probability. Int J Radiat Oncol Biol Phys 58 (2004) 1540-1548
21. Mueller A., Wallner K., Merrick G., et al. Modification of prostate implants based on postimplant treatment margin assessment. Med Phys 29 (2002) 2782-2787
22. Zelefsky M.J., Cohen G., Zakian K.L., et al. Intraoperative conformal optimization for transperineal prostate implantation using magnetic resonance spectroscopic imaging. Cancer J 6 (2000) 249-255
23. Ellis R.J., Sodee D.B., Spirnak J.P., et al. Feasibility and acute toxicities of radioimmunoguided prostate brachytherapy. Int J Radiat Oncol Biol Phys 48 (2000) 683-687
24. Torabi M., Aquino S.L., and Harisinghani M.G. Current concepts in lymph node imaging. J Nucl Med 45 (2004) 1509-1518
25. Chang S.S., and Heston W.D.W. The clinical role of prostate-specific membrane antigen (PSMA). Urol Oncol 7 (2002) 7-12
26. Wright G.L., Haley C., Beckett M., et al. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol 1 (1995) 18-28
27. DeWyngaert J.K., Noz M.E., Ellerin B., et al. Procedure for unmasking localization information from ProstaScint scans for prostate radiation therapy treatment planning. Int J Radiat Oncol Biol Phys 60 (2004) 654-662
28. In: Israel O., and Goldsmith S.J. (Eds). SPECT/CT imaging in clinical practice (2006), London: Informa Healthcare Publishing
29. Sodee D.B., Nelson A.D., Faulhaber P.F., et al. Update on fused capromab pendetide imaging of prostate cancer. Clin Prostate Cancer 3 (2005) 230-238
30. Ellis R.J., Kim E.Y., Conant R., et al. Radioimmunoguided imaging of prostate cancer foci with histopathological correlation. Int J Radiat Oncol Biol Phys 49 (2001) 1281-1286
31. Ellis R.J., Vertocnik A., Kim E., et al. Four-year biochemical outcome after radioimmunoguided transperineal brachytherapy for patients with prostate adenocarcinoma. Int J Radiat Oncol Biol Phys 57 (2003) 362-370
32. Ellis R.J., Vertocnik A., Sodee B., et al. Combination conformal radiotherapy and radioimmunoguided transperineal 103Pd implantation for patients with intermediate and unfavorable risk prostate adenocarcinoma. Brachytherapy 2 (2003) 215-222
33. Ellis R.J., Zhou H., Fu P., et al. SPECT/CT capromab pendetide independently predicts bDFS in long term outcome study. J Urol 174S (2006) 532 Abstract 1649
34. Burke H.B., and Henson D.E. The American Joint Committee on Cancer. Criteria for prognostic factors and for an enhanced prognostic system. Cancer 72 (1993) 3131-3135
35. Saw C.B., Meigooni A.S., and Nath R. Review of AAPM Task Group No. 43 recommendations on interstitial brachytherapy sources dosimetry. American Association of Physicists in Medicine. Med Dosim 23 (1998) 259-263
36. Beyer D., Nath R., Butler W., et al. American Brachytherapy Society recommendations for clinical implementation of NIST-1999 standards for (103) palladium brachytherapy. The clinical research committee of the American Brachytherapy Society. Int J Radiat Oncol Biol Phys 47 (2000) 273-275
37. Diggle P.J., Liang K.Y., and Zeger S.L. Analysis of longitudinal data (1994), Clarendon Press, Oxford
38. Tran A., Wallner K., Merrick G., et al. Rectal fistulas after prostate brachytherapy. Int J Radiat Oncol Biol Phys 63 (2005) 150-154
39. Herold D.M., Hanlon A.L., and Hanks G.E. Diabetes mellitus: A predictor for late radiation morbidity. Int J Radiat Oncol Biol Phys 43 (1999) 475-479
40. Skwarchuk M.W., Jackson A., Zelefsky M.J., et al. Late rectal toxicity after conformal radiotherapy of prostate cancer (I): Multivariate analysis and dose-response. Int J Radiat Oncol Biol Phys 47 (2000) 103-113
41. Zelefsky M.J., Chan H., Hunt M., et al. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 176 4 Pt. 1 (2006) 1415-1419
42. Zaider M., Zelefsky M.J., Lee E.K., et al. Treatment planning for prostate implants using magnetic-resonance spectroscopy imaging. Int J Radiat Oncol Biol Phys 47 (2000) 1085-1096
43. Roach III M. Reducing the toxicity associated with the use of radiotherapy in men with localized prostate cancer. Urol Clin North Am 31 (2004) 353-366